source
- ai3Bio raises $48 million to develop T-helper cell-targeted immune-reset therapiesai3Bio, a new biotech startup formed from Corner Therapeutics and Novasenta, announced it has secured $48 million in an early-stage venture capital round. The company aims to create treatments for…
- UniQure tumbles with latest data for Huntington’s gene therapyAnalysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."BioPharma Dive · 21d ago↗ source